Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425957 | 0.95 | SIGMAR1 (0.90) | SIGMAR1POLBHTTKMT2ACCR3 | |
| SCHEMBL20797123 | 0.90 | SIGMAR1 (0.81) | SIGMAR1POLBHTTKMT2ALTA4H | |
| Sulfurous Acid SCHEMBL28001231 | 0.89 | SIGMAR1 (0.79) | SIGMAR1POLBHTTKMT2ALTA4H | |
| SCHEMBL78043 | 0.89 | SIGMAR1 (0.79) | SIGMAR1POLBHTTKMT2ACCR3 | |
| SCHEMBL9539677 | 0.89 | SIGMAR1 (0.79) | SIGMAR1POLBHTTKMT2ACCR3 | |
| SCHEMBL2962629 | 0.86 | SIGMAR1 (1.00) | SIGMAR1POLBLTA4HCCR3 | |
| SCHEMBL6550825 | 0.86 | SIGMAR1 (1.00) | SIGMAR1POLBLTA4HCCR3 | |
| SCHEMBL29642998 | 0.86 | SIGMAR1 (0.74) | SIGMAR1POLBHTTKMT2ALTA4H | |
| Ethylene SCHEMBL28207535 | 0.85 | SIGMAR1 (0.74) | SIGMAR1POLBHTTKMT2ACCR3 | |
| SCHEMBL28306965 | 0.85 | SIGMAR1 (0.72) | SIGMAR1POLBHTTKMT2ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0507863-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | — | 1993-07-07 | — | — | EP | claimed |
| EP-0507863-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | claimed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| CN-109232458-A | A kind of preparation method of chirality morpholinium compound | 南通常佑药业科技有限公司 | 2019-01-18 | — | — | CN | disclosed |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-11-08 | — | — | US | disclosed |
| US-8268873-B2 | Use of 1-Cyanobutan-2-yl-1-[3-[3-[3-methoxy-4-(oxazol-5-yl)phenyl]ureido]phenyl] ethylcarbamate, AVN 944, VX-944 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2481407-A1 | Compounds for use in treating cognitive disorders | Allergan, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-02-02 | — | — | US | disclosed |
| US-6946279-B2 | THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS FOR PRODUCING THE SAME | FUJIMORI KOGYO CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| WO-2005077884-A2 | HYDROAMINOMETHYLATION OF OLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20040096953-A1 | Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing composition, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same, | JNC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1371663-A1 | THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS | FUJIMORI KOGYO CO., LTD. (JP) | 2003-12-17 | — | — | EP | disclosed |
| EP-1265844-A1 | METHOD FOR PRODUCING AMINES BY THE HYDROAMINOMETHYLATION OF OLEFINS IN THE PRESENCE OF IONIC LIQUIDS | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001064621-A1 | METHOD FOR PRODUCING AMINES BY THE HYDROAMINOMETHYLATION OF OLEFINS IN THE PRESENCE OF IONIC LIQUIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| EP-0008686-B1 | SYNTHESIS OF PHENYL-PROPYL MORPHOLINE AND PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-04-20 | — | — | EP | disclosed |
| EP-0009077-B1 | SUBSTITUTED PHENYLPROPYL HALIDES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| EP-0008686-A2 | Synthesis of phenyl-propyl morpholine and piperidine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096953-A1 | Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing composition, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same, | FGB, F2, TFPI | SIGMAR1 4882/4885POLB 4250/4885HTT 3512/4885 |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | SIGMAR1 143/4885POLB 4518/4885HTT 1374/4885 |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | SIGMAR1 143/4885POLB 4518/4885HTT 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.